Stonehage Fleming Financial Services’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,599
| Closed | -$1.29M | – | 261 |
|
|
2024
Q1 | $1.29M | Buy |
+15,599
| New | +$1.2M | 0.08% | 33 |
|
|
2023
Q4 | – | Sell |
-2,689
| Closed | -$202K | – | 254 |
|
|
2023
Q3 | $202K | Sell |
2,689
-3,980
| -60% | -$306K | 0.02% | 148 |
|
|
2023
Q2 | $514K | Sell |
6,669
-8,930
| -57% | -$712K | 0.02% | 104 |
|
|
2023
Q1 | $1.29M | Hold |
15,599
| – | – | 0.08% | 33 |
|
|
2022
Q4 | $1.34M | Sell |
15,599
-1,600
| -9% | -$127K | 0.1% | 32 |
|
|
2022
Q3 | $1.06M | Hold |
17,199
| – | – | 0.08% | 34 |
|
|
2022
Q2 | $1.06M | Sell |
17,199
-1,500
| -8% | -$92.9K | 0.04% | 63 |
|
|
2022
Q1 | $1.11M | Hold |
18,699
| – | – | 0.03% | 72 |
|
|
2021
Q4 | $1.36M | Sell |
18,699
-1,399
| -7% | -$96.4K | 0.04% | 66 |
|
|
2021
Q3 | $1.41M | Sell |
20,098
-110
| -0.5% | -$7.73K | 0.04% | 63 |
|
|
2021
Q2 | $1.39M | Sell |
20,208
-960
| -5% | -$64.1K | 0.04% | 66 |
|
|
2021
Q1 | $1.37M | Sell |
21,168
-7,690
| -27% | -$496K | 0.05% | 66 |
|
|
2020
Q4 | $1.68M | Sell |
28,858
-10,500
| -27% | -$634K | 0.06% | 61 |
|
|
2020
Q3 | $2.48M | Sell |
39,358
-705
| -2% | -$48.9K | 0.09% | 39 |
|
|
2020
Q2 | $3.08M | Buy |
40,063
+6,103
| +18% | +$468K | 0.21% | 30 |
|
|
2020
Q1 | $2.54M | Buy |
33,960
+12,300
| +57% | +$850K | 0.13% | 32 |
|
|
2019
Q4 | $1.41M | Sell |
21,660
-4,640
| -18% | -$302K | 0.06% | 53 |
|
|
2019
Q3 | $1.67M | Buy |
26,300
+540
| +2% | +$35.3K | 0.08% | 45 |
|
|
2019
Q2 | $1.74M | Hold |
25,760
| – | – | 0.09% | 41 |
|
|
2019
Q1 | $1.68K | Sell |
25,760
-4,170
| -14% | -$277K | 0.08% | 49 |
|
|
2018
Q4 | $1.87M | Hold |
29,930
| – | – | 0.11% | 48 |
|
|
2018
Q3 | $2.29M | Buy |
29,930
+1,300
| +5% | +$98.2K | 0.13% | 44 |
|
|
2018
Q2 | $2.03M | Sell |
28,630
-3,850
| -12% | -$272K | 0.09% | 55 |
|
|
2018
Q1 | $2.45M | Sell |
32,480
-7,156
| -18% | -$569K | 0.16% | 43 |
|
|
2017
Q4 | $2.84M | Sell |
39,636
-16,090
| -29% | -$1.22M | 0.15% | 40 |
|
|
2017
Q3 | $4.52M | Buy |
55,726
+10,430
| +23% | +$798K | 0.22% | 38 |
|
|
2017
Q2 | $3.21M | Sell |
45,296
-22,535
| -33% | -$1.5M | 0.2% | 43 |
|
|
2017
Q1 | $4.61M | Sell |
67,831
-44,321
| -40% | -$3.12M | 0.3% | 37 |
|
|
2016
Q4 | $8.06M | Sell |
112,152
-4,170
| -4% | -$310K | 0.5% | 33 |
|
|
2016
Q3 | $9.2M | Buy |
116,322
+11,324
| +11% | +$920K | 0.55% | 34 |
|
|
2016
Q2 | $8.76M | Buy |
104,998
+9,700
| +10% | +$861K | 0.58% | 33 |
|
|
2016
Q1 | $8.75M | Buy |
95,298
+36,546
| +62% | +$3.3M | 0.57% | 32 |
|
|
2015
Q4 | $5.95M | Sell |
58,752
-622
| -1% | -$64.7K | 0.49% | 34 |
|
|
2015
Q3 | $5.83M | Buy |
59,374
+4,520
| +8% | +$502K | 0.62% | 31 |
|
|
2015
Q2 | $6.42M | Buy |
54,854
+11,600
| +27% | +$1.27M | 0.77% | 29 |
|
|
2015
Q1 | $4.25M | Hold |
43,254
| – | – | 0.51% | 32 |
|
|
2014
Q4 | $4.08M | Buy |
+43,254
| New | +$4.47M | 0.49% | 33 |
|
Other funds holding GILD
Stonehage Fleming Financial Services's GILD Position: Q2 2024 in Review
Stonehage Fleming Financial Services sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 15,599 shares — an estimated $1.29M sold.
Stonehage Fleming Financial Services first reported a position in GILD in Q4 2014 and held it in 37 quarters. The position peaked at $9.2M in Q3 2016. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.
- Stonehage Fleming Financial Services reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
- Stonehage Fleming Financial Services sold 15,599 Gilead Sciences shares in Q2 2024, an estimated $1.29M.
- Stonehage Fleming Financial Services first reported a position in Gilead Sciences in Q4 2014 and held it in 37 quarters.
- Stonehage Fleming Financial Services's Gilead Sciences position peaked at $9.2M in Q3 2016.
- 1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.
Based on Stonehage Fleming Financial Services's 13F filing for Q2 2024, filed 5 Aug 2024.